ArticleANZ journal of surgery
Breast Angiosarcoma: 15-Years Experience.
Article in ANZ journal of surgery. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast angiosarcoma is a rare, aggressive malignancy that can be primary (PAS) or secondary (SAS). This study evaluates the management and outcomes of breast angiosarcoma in a single-center breast/surgical oncology unit.
methodsA retrospective review was conducted on patients with histologically confirmed PAS or SAS who underwent surgical resection at Mater Hospital Brisbane between 2009 and 2024. Patient characteristics, clinical features, treatment, complications, and survival outcomes were analyzed.
resultsFifteen patients were included-4 with PAS and 11 with SAS. SAS patients were significantly older, all had a history of breast cancer treated with adjuvant radiotherapy, and commonly presented with skin discoloration (bruising or violaceous rash). There was a trend toward a shorter duration from presentation to diagnosis and fewer investigations required in PAS patients. Management did not differ between PAS and SAS groups; all patients underwent surgical resection and less than half received adjuvant radiotherapy or chemotherapy. Median follow-up was 27 months for PAS patients and 12 months for SAS patients. The local recurrence rate in the SAS group was 9.1%, with no local recurrence observed in the PAS group (p = 0.53). Mortality rates were 25% in the PAS group and 18.2% in the SAS group (p = 0.77).
conclusionBreast angiosarcoma has a poor prognosis with high recurrence and mortality. Diagnosis is difficult due to its rarity, subtle symptoms, and non-specific imaging. Clinicians should maintain a high index of suspicion to facilitate early diagnosis and referral to dedicated sarcoma/breast units for optimal management of this rare malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.